产品
编 号：F761303
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 906068-56-2
产品详情
生物活性：
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis.
体内研究：
Theralizumab (0.1-2 mg/kg，静脉注射) 在人源化小鼠模型中诱导淋巴细胞减少和人类细胞因子释放。Animal Model:Humanized mice model
Dosage:0.1-2 mg/kg
Administration:i.v.
Result:Caused loss of hCD45+ cells of about 60% at 2 mg/kg from the peripheral blood.
体外研究：
Theralizumab (5 μg/mL，4 天) 可增加高密度 (HD) 预培养后 PBMC 中 CD4+ T 细胞的分裂，并诱导炎症细胞因子的释放。
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis.
体内研究：
Theralizumab (0.1-2 mg/kg，静脉注射) 在人源化小鼠模型中诱导淋巴细胞减少和人类细胞因子释放。Animal Model:Humanized mice model
Dosage:0.1-2 mg/kg
Administration:i.v.
Result:Caused loss of hCD45+ cells of about 60% at 2 mg/kg from the peripheral blood.
体外研究：
Theralizumab (5 μg/mL，4 天) 可增加高密度 (HD) 预培养后 PBMC 中 CD4+ T 细胞的分裂，并诱导炎症细胞因子的释放。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备